Baiyunshan announcement: Qixing Pharmaceuticals, a subsidiary, has received the Chinese patent medicine registration certificate issued by the Macau Special Administrative Region Government Pharmaceutical Supervision and Administration Bureau for its pearl powder product. In 2023, Qixing Pharmaceuticals' sales revenue of pearl powder was RMB 4.8264 million, with about RMB 0.012 million in R&D expenses. This pharmaceutical will be manufactured by Guangdong Ozhen Pharmaceutical Co., Ltd. and sold in Macau, which will help to expand overseas business and enhance product market competitiveness. This registration has no significant impact on the company's current performance.
白云山：子公司获澳门药品注册证书
Baiyunshan: Subsidiary Obtains Pharmaceutical Registration Certificate of Macau.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.